Business Wire

PAYRETAILERS

11.5.2023 15:28:33 CEST | Business Wire | Press release

Share
PayRetailers Appoints Jonathan Wilson as Chief Risk Officer

PayRetailers, LATAM’s leading all-in-one payment technology provider, has appointed Jonathan Wilson as its new Chief Risk Officer (CRO). With this appointment, PayRetailers is taking another step forward in its mission to provide secure and reliable payment solutions to its growing customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005026/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jonathan Wilson, Chief Risk Officer at PayRetailers (Photo: PayRetailers)

As CRO, Wilson will be responsible for overseeing the company’s operational and credit risk as well as risk management strategy.

A risk management heavyweight

Jonathan Wilson boasts industry leading experience reducing risk exposure and elevating security profiles for cutting-edge global payments organizations. He served as Head of Risk for the Digital Wallets division at PaySafe for over a decade, where he led on risk management and data analytics, and implemented a control framework and anti-fraud and anti-money laundering practices.

Prior to joining PayRetailers, Wilson was Chief Risk and Compliance Officer (CRCO) at AU10TIX, responsible for providing identity verification and fraud detection services to numerous services and fintech businesses. As CRCO, he led his team through the development of a new enterprise risk management framework and risk management processes.

Wilson’s professional experience also encompasses assessing risk management effectiveness, identifying operational and financial risks, and implementing innovative internal controls, policies and processes to reduce risk and monitoring results of implemented improvement. He has managed relationships with domestic and international regulatory oversight organizations, and built awareness by aligning key stakeholders enterprise-wide.

The appointment comes at a time of strong growth for PayRetailers, as it continues to expand to new markets in Latin America and bolsters its senior leadership team.

Jonathan Wilson, Chief Risk Officer at PayRetailers, commented: “PayRetailers is playing a critical role as it delivers financial opportunity to underbanked markets across LATAM. It’s an exciting opportunity to bring my risk and compliance experience to a company with a clear vision and powerful purpose. PayRetailers is driving impressive growth that demands impeccable risk and compliance - as the company provides high quality, secure and easy to use payment platforms to retailers across the region.”

Juan Pablo Jutgla, CEO & Founder of PayRetailers, commented: “Jonathan strengthens the PayRetailers offering as he brings world-class expertise in developing and implementing effective risk management processes. As we continue to expand into new markets, grow into new verticals, and deliver new products, risk management becomes and increasing priority. Wilson will play an invaluable role in elevating our control mechanisms to ensure we continue to provide safe and reliable payment solutions to our customers.”

For more information about PayRetailers, please visit the company's website at https://payretailers.com

About PayRetailers

Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offer global merchants more than payment methods without the need of a local entity.

PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions.

PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay, Peru and Uruguay.

Website: https://www.payretailers.com

LinkedIn: https://www.linkedin.com/company/pay-retailers/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005026/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye